Clin2
NCT07140328Possibly a fitRecruiting

Testing a new inhaler for COPD symptoms

Chronic Obstructive Lung Disease (COLD)

Part of Lungs & breathing clinical trials.

This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
50 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • You must be between 40 and 80 years old.
  • You must have a COPD diagnosis confirmed by a breathing test (spirometry) within the last year.
  • Your breathing test must show that your lung function is between 30% and 80% of normal for your age.
  • Your COPD must have been stable (no flare-ups) for at least 4 weeks before screening.
  • You must be able to stop using other COPD medications during the study (except for the rescue inhaler provided).
  • You must be a current or former smoker with at least a 10 pack-year smoking history (like smoking 1 pack a day for 10 years), or have another significant risk factor.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07425210Not yet recruiting· Phase 2
Long-term safety study of HSK39004 inhaler for COPD

This study tests a new dry powder inhaler (HSK39004) for long-term safety in people with moderate to severe COPD. It may help if your breathing is limited despite current treatment.

Guiyang, Guizhou
NCT07583849Recruiting· Phase 3
Testing a new inhaled powder for COPD symptoms

This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.

Beijing, Beijing Municipality
NCT07658339Not yet recruiting· Phase 3
Testing an inhaled drug for COPD symptoms

This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.

Beijing
NCT07634367Not yet recruiting· Phase 3
Long-term safety of HSK39004 inhaled medicine for COPD

This study tests whether a new inhaled medication called HSK39004 is safe and effective for people with moderate to severe COPD (a lung disease that makes breathing difficult). You would use this medicine regularly over a long period and have your lung function and symptoms checked.

Nanchang, Jiangxi
NCT07116915Recruiting· Phase 1
Testing a new COPD inhaler for safety and effectiveness

This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.

Chengdu, Sichuan
NCT07035652Not yet recruiting· Phase 1
Testing XH-S004 tablets for COPD over multiple doses

This trial tests an experimental tablet called XH-S004 for people with moderate-to-severe COPD. It looks at how safe the drug is, how the body processes it, and if it helps symptoms.

Beijing, Beijing Municipality

Hear when a new Chronic Obstructive Lung Disease (COLD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.